Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Capricor Therapeutics To Host July 29 Webinar With PPMD On Deramiocel BLA Progress And Cardiomyopathy In Duchenne Muscular Dystrophy

Author: Benzinga Newsdesk | July 28, 2025 08:07am

Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that it will host a webinar in collaboration with Parent Project Muscular Dystrophy (PPMD) to review the current status of Capricor's Biologics License Application (BLA) for Deramiocel, provide information about cardiomyopathy in Duchenne, and take questions from the community. The webinar will be held on Tuesday, July 29, 2025, at 1:00 p.m. ET.

Posted In: CAPR


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist